Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · bladder-landscape@3

GSM5359438

—

b3afacc3-bdf1-5771-8c44-e91125f36b71

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—
sex
Male

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V2+0.610
  • MYC_TARGETS_V1+0.560
  • MTORC1_SIGNALING+0.400
  • UNFOLDED_PROTEIN_RESPONSE+0.400
  • OXIDATIVE_PHOSPHORYLATION+0.340
  • E2F_TARGETS+0.310
  • G2M_CHECKPOINT+0.260
  • PROTEIN_SECRETION+0.260
  • REACTIVE_OXYGEN_SPECIES_PATHWAY+0.230
  • TGF_BETA_SIGNALING+0.230

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.500
  • INTERFERON_GAMMA_RESPONSE-0.410
  • APICAL_SURFACE-0.380
  • INFLAMMATORY_RESPONSE-0.380
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.340
  • IL6_JAK_STAT3_SIGNALING-0.340
  • COMPLEMENT-0.330
  • HEDGEHOG_SIGNALING-0.320
  • COAGULATION-0.300
  • ESTROGEN_RESPONSE_LATE-0.250

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

7 twins match this tumor's tissue · 3 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MNG1063
mng-umap@100
——0.891
2BS_G23JJAZY
brain-umap@2
Supratentorial Ependymoma—0.875
3BS_G23JJAZY
medullo-epn-umap@date-based
EPNSupratentorial EPN0.871
4SAMN03290931
melanoma-umap@29
——0.863
5SRR10900581
melanoma-umap@29
——0.851
6SRR12202462
bladder-landscape@3
——0.846
7MNG449
mng-umap@100
——0.842
8MDT-AP-2085
medullo-epn-umap@date-based
MedMedulloblastoma0.841
9TCGA-DQ-7588-01A-11R-2081-07
head-neck@1
——0.841
10MNG1011
mng-umap@100
——0.835

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 22 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V20.610Idelalisib— uncovered
MYC_TARGETS_V10.560Inavolisib— uncovered
MTORC1_SIGNALING0.400Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.400Idelalisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.340Remibrutinib— uncovered
E2F_TARGETS0.310Inavolisib— uncovered
G2M_CHECKPOINT0.260Inavolisib— uncovered
PROTEIN_SECRETION0.260Remibrutinib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.230Inavolisib— uncovered
TGF_BETA_SIGNALING0.230Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.220Inavolisib— uncovered
HYPOXIA0.210Idelalisib— uncovered
DNA_REPAIR0.170Idelalisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.120Remibrutinib— uncovered
GLYCOLYSIS0.120Inavolisib— uncovered
UV_RESPONSE_UP0.120Idelalisib— uncovered
ADIPOGENESIS0.100Inavolisib— uncovered
ANDROGEN_RESPONSE0.100Inavolisib— uncovered
NOTCH_SIGNALING0.060Inavolisib— uncovered
FATTY_ACID_METABOLISM0.030Inavolisib— uncovered